Aligos Therapeutics Q1 net loss narrows to $23.0M; NASH and COVID programs on track

Aligos Therapeutics, Inc.

2023-Q1 EPS reported -$0.53 revenue$140,000

Cash, cash equivalents and investments $103.5M as of March 31, 2023, vs $125.8M at Dec 31, 2022.
Net loss $23.0M ($0.53 per share) compared to $35.6M ($0.84) in Q1 2022.
R&D expenses decreased to $18.1M from $31.7M YoY due to wind-down of STOPS and ASO programs.
NASH gel cap formulation selected; Phase 2 IND filing remains on track for Q4 2023.
COVID-19 protease inhibitor CTA submitted in UK; first-in-human dosing expected mid-2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aligos Therapeutics, Inc. reported first quarter 2023 results: net income $23.0 million, EPS $(0.53).

Period: first quarter 2023
Net income: $23.0 million
EPS: $(0.53)
Result: reported results

Exact text from the filing

Net losses for the three months ended March 31, 2023, were $23.0 million or basic and diluted net loss per common share of $(0.53), compared to net losses of $35.6 million or basic and diluted net loss per common share of $(0.84) for the three months ended March 31, 2022.

View on SEC.gov

Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-002889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.